Research programme: cystic fibrosis therapy - Shire/Cystic Fibrosis Foundation Therapeutics

Drug Profile

Research programme: cystic fibrosis therapy - Shire/Cystic Fibrosis Foundation Therapeutics

Alternative Names: SHP 636

Latest Information Update: 01 Feb 2016

Price : $50

At a glance

  • Originator Shire
  • Developer Cystic Fibrosis Foundation Therapeutics; Shire
  • Class Gene therapies; RNA
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 01 Feb 2016 Preclinical trials in Cystic fibrosis in USA (Inhalation) before February 2016
  • 10 Dec 2014 Early research in Cystic fibrosis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top